ATE452204T1 - Screening-methoden unter verwendung eines strukturmodells von fih - Google Patents
Screening-methoden unter verwendung eines strukturmodells von fihInfo
- Publication number
- ATE452204T1 ATE452204T1 AT03758318T AT03758318T ATE452204T1 AT E452204 T1 ATE452204 T1 AT E452204T1 AT 03758318 T AT03758318 T AT 03758318T AT 03758318 T AT03758318 T AT 03758318T AT E452204 T1 ATE452204 T1 AT E452204T1
- Authority
- AT
- Austria
- Prior art keywords
- fih
- structural model
- structural
- screening methods
- chemical entity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Epidemiology (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Evolutionary Biology (AREA)
- Cardiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Computing Systems (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Complex Calculations (AREA)
- Feedback Control In General (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0224102A GB0224102D0 (en) | 2002-10-16 | 2002-10-16 | Inhibitors |
GB0226598A GB0226598D0 (en) | 2002-11-14 | 2002-11-14 | Chemical inhibitors |
PCT/GB2003/004492 WO2004035812A2 (en) | 2002-10-16 | 2003-10-16 | Asparaginyl hydroxylases and modulators thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE452204T1 true ATE452204T1 (de) | 2010-01-15 |
Family
ID=32109245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03758318T ATE452204T1 (de) | 2002-10-16 | 2003-10-16 | Screening-methoden unter verwendung eines strukturmodells von fih |
Country Status (11)
Country | Link |
---|---|
US (1) | US7778779B2 (de) |
EP (2) | EP1554394B1 (de) |
JP (1) | JP4465276B2 (de) |
AT (1) | ATE452204T1 (de) |
AU (1) | AU2003274330B2 (de) |
CA (1) | CA2502541A1 (de) |
DE (1) | DE60330587D1 (de) |
ES (1) | ES2337043T3 (de) |
MX (1) | MXPA05004033A (de) |
PL (1) | PL376770A1 (de) |
WO (1) | WO2004035812A2 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1733030A2 (de) | 2004-03-26 | 2006-12-20 | Isis Innovation Limited | Tests zur identifizierung von modulatoren der hydroxylierung von ankyrin-repeat-proteinen durch 2-oxoglutarat-abhängige oxygenase und verfahren zur verwendung davon |
US7541357B2 (en) | 2004-07-15 | 2009-06-02 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
GB0519605D0 (en) | 2005-09-26 | 2005-11-02 | Isis Innovation | Assay |
US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
EP2327696A1 (de) | 2006-06-26 | 2011-06-01 | Warner Chilcott Company, LLC | Prolylhydroxylase-Hemmer und Verfahren zu ihrer Anwendung |
WO2009002533A1 (en) * | 2007-06-27 | 2008-12-31 | The Brigham And Women's Hospital, Inc. | Inflammatory bowel disease therapies |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
EP2379715B1 (de) * | 2008-12-19 | 2016-10-26 | European Molecular Biology Laboratory (Embl) | Polypeptidfragmente mit endonuklease-aktivität und deren verwendung |
PE20120373A1 (es) * | 2009-05-12 | 2012-05-17 | Albany Molecular Res Inc | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina |
CN102458123A (zh) * | 2009-05-12 | 2012-05-16 | 阿尔巴尼分子研究公司 | 芳基、杂芳基和杂环取代的四氢异喹啉及其用途 |
WO2010132487A1 (en) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
NZ600400A (en) | 2009-11-06 | 2014-09-26 | Aerpio Therapeutics Inc | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
NZ731621A (en) | 2009-12-04 | 2019-01-25 | Sunovion Pharmaceuticals Inc | Multicyclic compounds and methods of use thereof |
GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
MX2013014310A (es) | 2011-06-06 | 2014-01-23 | Akebia Therapeutics Inc | Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer. |
NO2686520T3 (de) | 2011-06-06 | 2018-03-17 | ||
GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
CN104902889A (zh) * | 2012-09-21 | 2015-09-09 | 罗得岛医院 | 用于治疗癌症的β-水解酶抑制剂 |
NZ753905A (en) | 2013-06-13 | 2020-07-31 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
US11324734B2 (en) | 2015-04-01 | 2022-05-10 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
US10312653B2 (en) | 2015-05-06 | 2019-06-04 | Milwaukee Electric Tool Corporation | Hydraulic tool |
KR20190065246A (ko) | 2016-07-29 | 2019-06-11 | 선오비온 파마슈티컬스 인코포레이티드 | 화합물 및 조성물 및 이들의 용도 |
IL264446B1 (en) | 2016-07-29 | 2024-05-01 | Pgi Drug Discovery Llc | Compounds and compositions and their use |
IL268694B2 (en) | 2017-02-16 | 2023-10-01 | Sunovion Pharmaceuticals Inc | Treatment of schizophrenia |
EP3661929B1 (de) | 2017-08-02 | 2021-07-14 | Sunovion Pharmaceuticals Inc. | Isochromanverbindungen und verwendungen davon |
WO2019161238A1 (en) | 2018-02-16 | 2019-08-22 | Sunovion Pharmaceuticals Inc. | Salts, crystal forms, and production methods thereof |
US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
AU2020236225A1 (en) | 2019-03-14 | 2021-09-16 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
US11738002B2 (en) | 2020-04-14 | 2023-08-29 | Sunovion Pharmaceuticals Inc. | Methods of treating neurological and psychiatric disorders |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001251467A1 (en) | 2000-05-17 | 2001-12-03 | Princeton University | Methods of making models, methods of using models of murg, compounds that bind, inhibit or stimulate muret proteins, and therapeutic compositions thereof |
GB0017323D0 (en) | 2000-07-15 | 2000-08-30 | Univ St Andrews | Enzyme |
ES2282292T3 (es) | 2000-09-22 | 2007-10-16 | Wyeth | Estructura cristalina de bace y usos de la misma. |
EP1379630B1 (de) | 2001-03-21 | 2012-09-26 | Isis Innovation Limited | Hif hydroxylase, methoden, mittel und testverfahren diesselbe betreffend |
AUPR773801A0 (en) | 2001-09-18 | 2001-10-11 | Adelaide Research & Innovation Pty Ltd | Asparagine hydroxylation of the cad domain of a hif protein |
-
2003
- 2003-10-16 PL PL376770A patent/PL376770A1/pl unknown
- 2003-10-16 AU AU2003274330A patent/AU2003274330B2/en not_active Ceased
- 2003-10-16 MX MXPA05004033A patent/MXPA05004033A/es not_active Application Discontinuation
- 2003-10-16 DE DE60330587T patent/DE60330587D1/de not_active Expired - Lifetime
- 2003-10-16 AT AT03758318T patent/ATE452204T1/de not_active IP Right Cessation
- 2003-10-16 JP JP2004544485A patent/JP4465276B2/ja not_active Expired - Fee Related
- 2003-10-16 EP EP03758318A patent/EP1554394B1/de not_active Expired - Lifetime
- 2003-10-16 CA CA002502541A patent/CA2502541A1/en not_active Abandoned
- 2003-10-16 US US10/531,662 patent/US7778779B2/en not_active Expired - Fee Related
- 2003-10-16 ES ES03758318T patent/ES2337043T3/es not_active Expired - Lifetime
- 2003-10-16 WO PCT/GB2003/004492 patent/WO2004035812A2/en active Application Filing
- 2003-10-16 EP EP09014486A patent/EP2156830A1/de not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2006504415A (ja) | 2006-02-09 |
US20070048728A1 (en) | 2007-03-01 |
WO2004035812A3 (en) | 2004-08-19 |
DE60330587D1 (de) | 2010-01-28 |
WO2004035812A2 (en) | 2004-04-29 |
EP1554394A2 (de) | 2005-07-20 |
CA2502541A1 (en) | 2004-04-29 |
JP4465276B2 (ja) | 2010-05-19 |
MXPA05004033A (es) | 2005-06-08 |
EP2156830A1 (de) | 2010-02-24 |
AU2003274330B2 (en) | 2009-06-04 |
US7778779B2 (en) | 2010-08-17 |
AU2003274330A1 (en) | 2004-05-04 |
ES2337043T3 (es) | 2010-04-20 |
PL376770A1 (pl) | 2006-01-09 |
EP1554394B1 (de) | 2009-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE452204T1 (de) | Screening-methoden unter verwendung eines strukturmodells von fih | |
Thien et al. | Determination of bioavailable phosphorus in soil | |
Chanton et al. | Quantifying methane oxidation from landfills using stable isotope analysis of downwind plumes | |
Livingstone et al. | The prediction of hypolimnetic oxygen profiles: a plea for a deductive approach | |
ATE488251T1 (de) | Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen | |
SE0201812D0 (sv) | Dynamic on-line optimization of production processes | |
DE10345743A1 (de) | Verfahren und Vorrichtung zum Bestimmen von Position und Orientierung einer Bildempfangseinrichtung | |
DK0944731T3 (da) | Enzymsensor | |
DE60334365D1 (de) | Leistungsverbesserung einer analytenüberwachungsvorrichtung | |
EA200501193A1 (ru) | Улучшенный способ и система для выявления и/или прогнозирования биологических аномалий, например церебральных нарушений | |
ATE462710T1 (de) | Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert | |
ATE296112T1 (de) | Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12 | |
ATE496141T1 (de) | Verfahren und system zum analysieren von reaktionen unter verwendung eines informationssystems | |
ATE507512T1 (de) | Verfahren, computerprogramm mit programmcode- mitteln und computerprogramm-produkt zur analyse von einflussgrössen auf einen brennvorgang in einer brennkammer unter verwendung eines trainierbaren, statistischen modells | |
DE602006017058D1 (de) | Verfahren zur stratifizierung von herzinsuffizienz | |
ATE279769T1 (de) | Vorrichtung und verfahren zum analysieren eines audiosignals hinsichtlich von rhythmusinformationen | |
ATE459077T1 (de) | Verfahren und vorrichtung zur bestimmung der aufzeichnungsparameter von optischen platten | |
ATE221657T1 (de) | Entstörung durch rheumafaktoren | |
DE69928250D1 (de) | Analytisches verfahren unter verwendung von multipelviren-markierung | |
ATE534903T1 (de) | Latex-reaktionsmittel zur adiponectinanalyse und verfahren zur adiponectinanalyse | |
Lu et al. | Multivariate calibration models based on the direct analysis of near-infrared single-beam spectra | |
DE602006007734D1 (de) | Verfahren und system zur echtzeitanalyse von biosensordaten | |
DE3850346D1 (de) | Verfahren zur Selbstdurchführung von Enzymkinetik. | |
Ziegler et al. | Testing the reliability of the Fiorillo bone surface abrasion scale | |
ATE355527T1 (de) | Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |